Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Interest & Investment Income (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Interest & Investment Income over the past 16 years, most recently at -$8.1 million for Q2 2025.

  • For Q2 2025, Interest & Investment Income fell 227.71% year-over-year to -$8.1 million; the TTM value through May 2025 reached -$2.4 million, down 178.05%, while the annual FY2025 figure was -$21.8 million, 536.96% down from the prior year.
  • Interest & Investment Income for Q2 2025 was -$8.1 million at Lifecore Biomedical, Inc. \De\, down from -$641000.0 in the prior quarter.
  • Over five years, Interest & Investment Income peaked at $6.3 million in Q2 2024 and troughed at -$8.1 million in Q2 2025.
  • A 5-year average of -$365600.0 and a median of $16000.0 in 2022 define the central range for Interest & Investment Income.
  • On a YoY basis, Interest & Investment Income climbed as much as 9202.94% in 2024 and fell as far as 15409.09% in 2024.
  • Year by year, Interest & Investment Income stood at $19000.0 in 2021, then fell by 15.79% to $16000.0 in 2022, then surged by 325.0% to $68000.0 in 2023, then crashed by 77.94% to $15000.0 in 2024, then tumbled by 53960.0% to -$8.1 million in 2025.
  • Business Quant data shows Interest & Investment Income for LFCR at -$8.1 million in Q2 2025, -$641000.0 in Q1 2025, and $15000.0 in Q3 2024.